ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

doi:10.3748/wjg.14.6401

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2863)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

308

HTML

2260

Figures (1-5)

166

Tables (1-2)

129

Sum=2863

Nov 7, 2008 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 7, 2008; 14(41): 6401-6407
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401

Full Size Figure Download Figure

Figure 5 Overall survival curves of gastric cancer patients according to ERCC1 mRNA expression and ERCC1 118 C/T polymorphism survival curves according to ERCC1 mRNA levels (A) or ERCC1 118 polymorphism (B). The overall survival in patients with low level of ERCC1 mRNA was significantly longer than that in patients with high levels (P < 0.05), while there was no significant difference found between patients with ERCC1 118 C/C and variant genotypes (T/T or C/T).

Citation: Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008; 14(41): 6401-6407
URL: https://www.wjgnet.com/1007-9327/full/v14/i41/6401.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6401